110 related articles for article (PubMed ID: 17673813)
1. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Verstovsek S; Komatsu N; Gill H; Jin J; Lee SE; Hou HA; Sato T; Qin A; Urbanski R; Shih W; Zagrijtschuk O; Zimmerman C; Mesa RA
Future Oncol; 2022 Sep; 18(27):2999-3009. PubMed ID: 35924546
[TBL] [Abstract][Full Text] [Related]
2. Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Shide K; Takenaka K; Kitanaka A; Numata A; Kameda T; Yamauchi T; Inagaki A; Mizuno S; Takami A; Ito S; Hagihara M; Usuki K; Maekawa T; Sunami K; Ueda Y; Tsutsui M; Ando M; Komatsu N; Ozawa K; Kurokawa M; Arai S; Mitani K; Akashi K; Shimoda K
Ann Hematol; 2024 Jan; 103(1):97-103. PubMed ID: 37946031
[TBL] [Abstract][Full Text] [Related]
3. [Research status and challenges of advanced myeloproliferative neoplasms].
Bai J; Zhang YH; Shao ZH
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3603-3607. PubMed ID: 38018058
[TBL] [Abstract][Full Text] [Related]
4. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Barosi G; Mesa RA; Thiele J; Cervantes F; Campbell PJ; Verstovsek S; Dupriez B; Levine RL; Passamonti F; Gotlib J; Reilly JT; Vannucchi AM; Hanson CA; Solberg LA; Orazi A; Tefferi A;
Leukemia; 2008 Feb; 22(2):437-8. PubMed ID: 17728787
[No Abstract] [Full Text] [Related]
5. Bone marrow findings post allogeneic transplant for myeloproliferative neoplasms and chronic myelomonocytic leukemia with increased fibrosis.
Gupta S; Courville EL
Lab Med; 2024 Apr; ():. PubMed ID: 38603517
[TBL] [Abstract][Full Text] [Related]
6. Renal tubular necrosis associated with anagrelide administration: a case report.
Sawase A; Kitamura M; Morimoto M; Fukuda H; Uramatsu T; Katafuchi E; Yamashita H; Nakayama T; Mukae H; Nishino T
CEN Case Rep; 2024 Apr; ():. PubMed ID: 38658458
[TBL] [Abstract][Full Text] [Related]
7. Fibrosis identified in the bone marrow biopsies of patients with essential thrombocythemia: its incidence and significance for the differential diagnostic considerations.
Marcinek J; Plank L; Szépe P; Balhárek T
Cesk Patol; 2008 Jul; 44(3):62-6. PubMed ID: 18783136
[TBL] [Abstract][Full Text] [Related]
8. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.
Li N; Yao QM; Gale RP; Li JL; Li LD; Zhao XS; Jiang H; Jiang Q; Jiang B; Shi HX; Chen SS; Liu KY; Huang XJ; Ruan GR
Leuk Res; 2015 May; 39(5):510-4. PubMed ID: 25746303
[TBL] [Abstract][Full Text] [Related]
9. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
11. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
[TBL] [Abstract][Full Text] [Related]
12. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Birgegård G
Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
[TBL] [Abstract][Full Text] [Related]
13. Update on JAK2 Inhibitors in Myeloproliferative Neoplasm.
Chan D; Koren-Michowitz M
Ther Adv Hematol; 2011 Apr; 2(2):61-71. PubMed ID: 23556077
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow hyaluronan and reticulin in patients with malignant disorders.
Sundström G; Hultdin M; Engström-Laurent A; Dahl IM
Med Oncol; 2010 Sep; 27(3):618-23. PubMed ID: 19548126
[TBL] [Abstract][Full Text] [Related]
15. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
Campbell PJ; Bareford D; Erber WN; Wilkins BS; Wright P; Buck G; Wheatley K; Harrison CN; Green AR
J Clin Oncol; 2009 Jun; 27(18):2991-9. PubMed ID: 19364963
[TBL] [Abstract][Full Text] [Related]
16. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
Hultdin M; Sundström G; Wahlin A; Lundström B; Samuelsson J; Birgegård G; Engström-Laurent A
Med Oncol; 2007; 24(1):63-70. PubMed ID: 17673813
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
